Special Issue "Population Immunity and Persistence to SARS-CoV-2 Induced by Infection and Vaccination, Protection against New Infections and Implication for Further Vaccination"

Dear Colleagues,

Although the World Health Organization declared the end to COVID-19’s emergency phase, SARS-CoV-2 will be around for a long time and the risk of new variants remains. Having a good knowledge of the population immunity landscape and dynamics and understanding its protection against infections of variants and the severity after infections are critical for policymaking on actions that countries should take in the new phase of the COVID-19 pandemic. However, global, regional, and national population immunity and their dynamic changes remain unknown since it is complex and varied due to disparity of infection history and vaccination coverage across the world. The Special Issue aims to collect the latest research results on the sero-epidemiological characteristics of SARS-CoV-2 infections and vaccination. With this in mind, we are pleased to invite the submission of original research articles and reviews investigating the infection incidence and its severity, population immunity landscape, the kinetics of antibodies following prior infections (with any variant), vaccination (particularly post-licensure), or both (hybrid immunity), protection (and cross-protection) against new variants infections, and providing new ideas for the COVID-19 vaccination strategy in the future.

Looking forward to receiving your contributions.

Dr. Juan Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• SARS-CoV-2
• COVID-19
• serology
• population immunity
• hybrid immunity
• vaccination
• antibody kinetics
• cross-protection